Our pivotal study will include US and OUS centers, with the aim of evaluating the safety and effectiveness of Agili-C™ compared to current surgical standard of care in traumatic and arthritic lesions. The study is designed as prospective, multicenter, open-label, randomized and controlled. It will be conducted in accordance with FDA regulations, Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines, and in compliance with the applicable local regulations.